Neovacs S.A. (ALNEV) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.144x

Based on the latest financial reports, Neovacs S.A. (ALNEV) has a cash flow conversion efficiency ratio of -0.144x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.60 Million ≈ $-3.04 Million USD) by net assets (€18.03 Million ≈ $21.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neovacs S.A. (ALNEV) total market value for the company's overall valuation and market capitalisation.

Neovacs S.A. - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Neovacs S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Neovacs S.A. for real-time trading data and today's change.

Neovacs S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neovacs S.A. ranked by their cash flow conversion efficiency. Review ALNEV FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Aquis Exchange PLC LSE:AQX	0.057x
Lexaria Bioscience Corp NASDAQ:LEXXW	-0.218x
Jasmine International Public Company Limited F:JASN	0.020x
Clene Inc NASDAQ:CLNNW	0.322x
Waldencast Acquisition Corp NASDAQ:WALDW	-0.003x
BriaCell Therapeutics Corp NASDAQ:BCTXW	-0.270x
Ucommune International Ltd NASDAQ:UKOMW	-0.017x
immatics biotechnologies GmbH NASDAQ:IMTXW	-0.064x

Annual Cash Flow Conversion Efficiency for Neovacs S.A. (2007–2025)

The table below shows the annual cash flow conversion efficiency of Neovacs S.A. from 2007 to 2025. Also see ALNEV current and non-current assets for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€18.03 Million ≈ $21.08 Million	€-5.03 Million ≈ $-5.88 Million	-0.279x	-39.98%
2024-12-31	€18.06 Million ≈ $21.12 Million	€-3.60 Million ≈ $-4.21 Million	-0.199x	-356.68%
2023-12-31	€43.82 Million ≈ $51.23 Million	€-1.91 Million ≈ $-2.24 Million	-0.044x	+56.59%
2022-12-31	€44.23 Million ≈ $51.71 Million	€-4.45 Million ≈ $-5.20 Million	-0.101x	+55.44%
2021-12-31	€43.90 Million ≈ $51.32 Million	€-9.91 Million ≈ $-11.58 Million	-0.226x	+56.14%
2020-12-31	€10.98 Million ≈ $12.84 Million	€-5.65 Million ≈ $-6.61 Million	-0.515x	+82.61%
2019-12-31	€2.74 Million ≈ $3.20 Million	€-8.10 Million ≈ $-9.47 Million	-2.958x	+45.82%
2018-12-31	€2.44 Million ≈ $2.85 Million	€-13.31 Million ≈ $-15.56 Million	-5.461x	+67.61%
2017-12-31	€845.75K ≈ $988.77K	€-14.26 Million ≈ $-16.67 Million	-16.857x	-92.46%
2016-12-31	€1.26 Million ≈ $1.47 Million	€-11.00 Million ≈ $-12.86 Million	-8.759x	-591.16%
2015-12-31	€6.07 Million ≈ $7.09 Million	€-7.69 Million ≈ $-8.99 Million	-1.267x	+12.37%
2014-12-31	€5.57 Million ≈ $6.51 Million	€-8.05 Million ≈ $-9.41 Million	-1.446x	+28.13%
2013-12-31	€3.48 Million ≈ $4.07 Million	€-7.00 Million ≈ $-8.18 Million	-2.012x	-15.00%
2012-12-31	€3.62 Million ≈ $4.23 Million	€-6.33 Million ≈ $-7.40 Million	-1.749x	-114.30%
2011-12-31	€10.57 Million ≈ $12.36 Million	€-8.63 Million ≈ $-10.09 Million	-0.816x	+16.59%
2010-12-31	€8.27 Million ≈ $9.67 Million	€-8.10 Million ≈ $-9.47 Million	-0.979x	-104.34%
2009-12-31	€-352.58K ≈ $-412.20K	€-7.95 Million ≈ $-9.29 Million	22.549x	+3373.12%
2008-12-31	€6.51 Million ≈ $7.61 Million	€-4.49 Million ≈ $-5.25 Million	-0.689x	+68.57%
2007-12-31	€1.97 Million ≈ $2.30 Million	€-4.32 Million ≈ $-5.05 Million	-2.192x	--

About Neovacs S.A.

PA:ALNEV France Biotechnology

Market Cap

$10.44

€8.93 EUR

Market Cap Rank

#32044 Global

#601 in France

Share Price

€0.19

Change (1 day)

+2.10%

52-Week Range

€0.00 - €1.89

All Time High

€3.13